---
schema_version: "secwatch.filing_event.v1"
accession: "0001665988-26-000010"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:42:24.064796+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q4 GAAP EPS $0.21, revenue $157.9M; guides FY2026 sales $600-610M

## Summary
- Q4 revenue $157.9M (+2.8% reported, +10.0% organic); GAAP EPS $0.21 (vs $0.00); non-GAAP EPS $0.24; Adj. EBITDA $36.7M (+30%).
- Full year 2025 revenue $568.1M (-0.9% reported, +7.5% organic); GAAP EPS $0.33 (vs -$0.56); Adj. EPS $0.68 (+21.4%).
- FY2026 guidance: net sales $600-610M (6-7% growth); Adj. EPS $0.73-$0.77 (7-13% growth); cash from ops $82-87M.
- Q4 cash from operations $38M (+97% YoY); full year cash from ops up 92%; debt reduced by $29M in Q4.
- Launched PNS products StimTrial and TalisMann; added Megan Rosengarten as SVP/GM PNS.

## SEC filing metadata
- accession: 0001665988-26-000010
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000010/0001665988-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000010/bvs-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001665988-26-000010
- JSON: https://secwatch.observer/filing/0001665988-26-000010.json
- Plain text: https://secwatch.observer/filing/0001665988-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.